Insurance and adherence to guideline concordant cervical cancer therapy do not reduce mortality?
PMID: 33092744 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 25, 2020 Category: Cancer & Oncology Authors: Brewster WR Tags: Gynecol Oncol Source Type: research

Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies.
CONCLUSION: Our findings support a prognostic role for elevated CAR and TLR besides that of NLR and PLR in advanced-FIGO stage cervical cancer. PMID: 33092868 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 19, 2020 Category: Cancer & Oncology Authors: Han X, Liu S, Yang G, Hosseinifard H, Imani S, Yang L, Maghsoudloo M, Fu S, Wen Q, Liu Q Tags: Gynecol Oncol Source Type: research

Society of Gynecologic Oncology recommendations for fellowship education during the COVID-19 pandemic and beyond: Innovating programs to optimize trainee success.
Abstract In approximately ten months' time, the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected over 34 million people and caused over one million deaths worldwide. The impact of this virus on our health, relationships, and careers is difficult to overstate. As the economic realities for academic medical centers come into focus, we must recommit to our core missions of patient care, education, and research. Fellowship education programs in gynecologic oncology have quickly adapted to the "new normal" of social distancing using video conferencing platforms to ...
Source: Gynecologic Oncology - October 17, 2020 Category: Cancer & Oncology Authors: Ferriss JS, Rose S, Rungruang B, Urban R, Spencer R, Uppal S, Sinno AK, Duska L, Walsh C Tags: Gynecol Oncol Source Type: research

Naples prognostic score is an independent prognostic factor in patients with operable endometrial cancer: Results from a retrospective cohort study.
CONCLUSION: High NPS is associated with poor PFS and OS and is a valuable independent prognostic factor in patients with EC. PMID: 33081984 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 17, 2020 Category: Cancer & Oncology Authors: Li Q, Cong R, Wang Y, Kong F, Ma J, Wu Q, Ma X Tags: Gynecol Oncol Source Type: research

Cervical cancer treatment initiation and survival: The role of residential proximity to cancer care.
CONCLUSIONS: For cervical cancer patients, driving time to chosen treatment providers, but not to the nearest cancer care provider, was associated with prolonged time to treatment initiation. Neither was associated with survival. PMID: 33081985 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 17, 2020 Category: Cancer & Oncology Authors: Hung P, Zahnd WE, Brandt HM, Adams SA, Wang S, Eberth JM Tags: Gynecol Oncol Source Type: research

A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Abstract BACKGROUND: We investigated the safety and efficacy of a combination of the oral tyrosine kinase inhibitor, nintedanib (BIBF 1120) with oral cyclophosphamide in patients with relapsed ovarian cancer. PATIENTS AND METHODS: Patients with relapsed ovarian, fallopian tube or primary peritoneal cancer received oral cyclophosphamide (100 mg o.d.) and were randomised (1,1) to also have either oral nintedanib or placebo. The primary endpoint was overall survival (OS). Secondary endpoints included progression free survival (PFS), response rate, toxicity, and quality of life. RESULTS: 117 patients we...
Source: Gynecologic Oncology - October 16, 2020 Category: Cancer & Oncology Authors: Hall MR, Dehbi HM, Banerjee S, Lord R, Clamp A, Ledermann JA, Nicum S, Lilleywhite R, Bowen R, Michael A, Feeney A, Glasspool R, Hackshaw A, Rustin G Tags: Gynecol Oncol Source Type: research

Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
CONCLUSIONS: Early-stage CCOC is associated with a longer RFI, similar CSS and a shorter prCSS compared to HGSOC. No prognostic differences were observed between CC and HGE OC. The relapse risk was the lowest in IA/IB/IC1 CC compared to HGS, whereas CC displayed poor sensitivity to chemotherapy after relapse. PMID: 33077259 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 16, 2020 Category: Cancer & Oncology Authors: Ceppi L, Grassi T, Galli F, Buda A, Aletti G, Lissoni AA, Adorni M, Garbi A, Colombo N, Bonazzi C, Landoni F, Fruscio R Tags: Gynecol Oncol Source Type: research

Evaluating the effect of a group pre-treatment chemotherapy psycho-education session for chemotherapy-naive gynecologic cancer patients and their caregivers.
The objective was to evaluate the effects of a pre-chemotherapy education class on chemotherapy-naïve patients diagnosed with gynecologic cancer and their informal caregivers. METHODS: A prospective cohort study was conducted at a cancer centre in Toronto, Canada. All women diagnosed with gynecologic cancer, who were scheduled to receive chemotherapy treatment, and their caregivers were invited to attend the GyneChemo class, newly introduced as the centre's standard of care. Consenting attendees were asked to complete pre-and post-class survey measures assessing anxiety, self-efficacy, information needs, prepared...
Source: Gynecologic Oncology - October 16, 2020 Category: Cancer & Oncology Authors: Samoil D, Abdelmutti N, Gallagher LO, Jivraj N, Quartey NK, Tinker L, Giuliani M, Trang A, Ferguson SE, Papadakos J Tags: Gynecol Oncol Source Type: research

Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
Abstract OBJECTIVE: To determine if natural language processing (NLP) with machine learning of unstructured full text documents (a preoperative CT scan) improves the ability to predict postoperative complication and hospital readmission among women with ovarian cancer undergoing surgery when compared with discrete data predictors alone. METHODS: Medical records from two institutions were queried to identify women with ovarian cancer and available preoperative CT scan reports who underwent debulking surgery. Machine learning methods using both discrete data predictors (age, comorbidities, preoperative laborato...
Source: Gynecologic Oncology - October 14, 2020 Category: Cancer & Oncology Authors: Barber EL, Garg R, Persenaire C, Simon M Tags: Gynecol Oncol Source Type: research

Radiotherapy is not indicated in patients with vulvar squamous cell carcinoma and only one occult intracapsular groin node metastasis.
CONCLUSION: Because of the low risk of groin recurrence and the excellent groin recurrence-free survival, we recommend that adjuvant radiotherapy to the groin in patients with vulvar squamous cell carcinoma and a single occult intracapsular lymph node metastasis can be safely omitted to prevent unnecessary toxicity and morbidity. PMID: 33067000 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 13, 2020 Category: Cancer & Oncology Authors: van der Velden J, Pleunis N, Barlow E, Zijlmans H, de Hullu J, Hacker NF, Fons G Tags: Gynecol Oncol Source Type: research

Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
CONCLUSIONS: In this retrospective cohort study, we demonstrate that in women with advanced EOC, HIPEC with MIS at the time of IDS following NACT is feasible. Our institutional experience demonstrates similar rates of R0 cytoreduction, compared to LAP. An MIS approach should not prevent surgeons from utilizing HIPEC where indicated for management of advanced EOC. PMID: 33067001 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 13, 2020 Category: Cancer & Oncology Authors: Morton M, Chambers LM, Costales AB, Chichura A, Gruner M, Horowitz MP, Rose PG, Yao M, Debernardo R, Michener C Tags: Gynecol Oncol Source Type: research

Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
CONCLUSIONS: SBRT offers a high rate of local control with low incidence of toxicity, mainly grade 1 GI toxicity and fatigue, and provides effective salvage therapy for oligometastatic extracranial pelvic and extra-pelvic gynecological tumors. PMID: 33059914 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 12, 2020 Category: Cancer & Oncology Authors: Reshko LB, Baliga S, Crandley EF, Harry Lomas IV, Richardson MK, Spencer K, Bennion N, Mikdachi HE, Irvin W, Kersh CR Tags: Gynecol Oncol Source Type: research

Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
CONCLUSIONS: Young EOC patients are most often diagnosed at an early FIGO stage with LG serous or mucinous histology. Tumors are significantly more resistant to platinum-based chemotherapy in younger patients. PMID: 33059915 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 12, 2020 Category: Cancer & Oncology Authors: Michels J, Genestie C, Dunant A, Caron O, Lanoy E, Colomba E, Pommeret F, Rey A, Gouy S, Duvillard P, Teuff GL, Larue C, Savoye AM, Lhommé C, Leary A, Morice P, Pautier P Tags: Gynecol Oncol Source Type: research

The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
Abstract Advances in next generation sequencing have allowed for rapid and economical germline and tumor genomic profiling. Targeted therapies based on molecular tumor profiling are now integrated into treatment guidelines for many solid tumors. In epithelial ovarian cancer, 50% of tumors possess damaging mutations in homologous recombination repair genes (aka homologous recombination deficiency or HRD) which includes the BRCA genes. Deleterious BRCA mutations and HRD have recently emerged as predictive biomarkers for the use of PARP inhibitors in ovarian cancer. Every patient with ovarian cancer must be referred ...
Source: Gynecologic Oncology - October 11, 2020 Category: Cancer & Oncology Authors: Haunschild CE, Tewari KS Tags: Gynecol Oncol Source Type: research

Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Abstract OBJECTIVE: To evaluate clinicopathologic characteristics and survival impact associated with mismatch repair (MMR) deficient subgroups of endometrial cancer (EC) in patients undergoing universal screening for Lynch Syndrome. METHODS: A retrospective cohort study using a prospectively maintained gynecologic oncology registry of patients who underwent surgery for EC was conducted. All pathology specimens underwent tumor testing using immunohistochemistry for MMR deficiency with reflex MLH1 promotor methylation testing. Tumors were classified as MMR-I (intact MMR expression), MMR-DM (MMR deficient due t...
Source: Gynecologic Oncology - October 9, 2020 Category: Cancer & Oncology Authors: Carr C, Son J, Yao M, Priyadarshini A, Marquard J, Vargas R, Michener C, AlHilli MM Tags: Gynecol Oncol Source Type: research

The relationship of human papillomavirus infection with endocervical glandular involvement on cone specimens in women with cervical intraepithelial neoplasia.
Abstract OBJECTIVE: The aim of study was to evaluate the association of endocervical gland involvement (EGI) on histological samples with high risk (HR) human papillomavirus (HPV) infection and with the persistence/recurrence rate of cervical intraepithelial neoplasia (CIN) after treatment. METHODS: A total of 1301 subjects who had conization procedures after cervical punch biopsies (533 persistent CIN1, 768 CIN2+ including 20 microinvasive cervical cancer) were enrolled in the study. HPV genotypes were identified using the INNO-LiPA HPV genotyping assay on cervical scraping. Logistic regression and Cox regre...
Source: Gynecologic Oncology - October 8, 2020 Category: Cancer & Oncology Authors: Arsenio S, Mattia D, Chiara BA, Stefania C, Giacomo F, Barbara G Tags: Gynecol Oncol Source Type: research

Comparison of long-term survival of total abdominal radical hysterectomy and laparoscopy-assisted radical vaginal hysterectomy in patients with early cervical cancer: Korean multicenter, retrospective analysis.
CONCLUSION: LARVH showed significant noninferiority for PFS and OS versus TARH in early cervical cancer, suggesting the potential oncologic safety of LARVH. PMID: 33041070 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 8, 2020 Category: Cancer & Oncology Authors: Kwon BS, Roh HJ, Lee S, Yang J, Song YJ, Lee SH, Kim KH, Suh DS Tags: Gynecol Oncol Source Type: research

Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer - a randomized controlled trial.
Abstract OBJECTIVE: The aim of this study was to assess the superiority of ICG-99mTc-nanocolloid for the intraoperative visual detection of sentinel lymph nodes (SLNs) in vulvar squamous cell carcinoma (VSCC) patients compared to standard SLN detection using 99mTc-nanocolloid with blue dye. METHODS: In this multicenter, randomized controlled trial, VSCC patients underwent either the standard SLN procedure or with the hybrid tracer ICG-99mTc-nanocolloid. The primary endpoint was the percentage of fluorescent SLNs compared to blue SLNs. Secondary endpoints were successful SLN procedures, surgical outcomes and p...
Source: Gynecologic Oncology - October 8, 2020 Category: Cancer & Oncology Authors: Deken MM, van Doorn HC, Verver D, Boogerd LSF, de Valk KS, Rietbergen DDD, van Poelgeest MIE, de Kroon CD, Beltman JJ, van Leeuwen FWB, Putter H, Braak JPBM, de Geus-Oei LF, van de Velde CJH, Burggraaf J, Vahrmeijer AL, Gaarenstroom KN Tags: Gynecol Oncol Source Type: research

Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
CONCLUSION: Maintenance letrozole is a cost-effective treatment strategy in patients with advanced LGSC resulting in clinically-relevant improvement in QALYs, LYs, and fewer disease recurrences. PMID: 33032821 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 6, 2020 Category: Cancer & Oncology Authors: Nica A, Lee JYJ, Hong NL, May T Tags: Gynecol Oncol Source Type: research

Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
CONCLUSIONS: BRIP1-deficient ovarian epithelial cells exhibit defective HR, resulting in synthetic lethality when exposed to a platinum agent/PARPi combination. PARPi alone had no effect; this lack of effect may result from distinguishing molecular properties of BRIP1and/or consequences of genomic background. Our study identifies altered BRIP1 as a target for precision medicine-based therapies for ovarian cancers. This investigation supports consideration of the use of a platinum agent/PARPi combination in ovarian cancers depending upon genetic profile and genomic background. PMID: 33032822 [PubMed - as supplied by pu...
Source: Gynecologic Oncology - October 5, 2020 Category: Cancer & Oncology Authors: Ciccone MA, Adams CL, Bowen C, Thakur T, Ricker C, Culver JO, Maoz A, Melas M, Idos GE, Jeyasekharan AD, Matsuo K, Roman LD, Gruber SB, McDonnell KJ Tags: Gynecol Oncol Source Type: research

High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
CONCLUSIONS: Our study supports the existence of clinically relevant marker- and localization defined macrophage subsets in HGSC, which are independently regulated. Moreover, it suggests stromal CD11c as a novel prognostic marker in HGSC. PMID: 33032823 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 5, 2020 Category: Cancer & Oncology Authors: Corvigno S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, Carlson JW, Fernebro J, Åvall-Lundqvist E, Kannisto P, Hedenfalk I, Malander S, Rolny C, Dahlstrand H, Östman A Tags: Gynecol Oncol Source Type: research

Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsy.
CONCLUSIONS: LEEP was not associated with a greater likelihood of positive margins, specimen fragmentation or smaller excision compared to CKC when performed according to a standardized protocol. However, the study was not powered to establish non-inferiority of LEEP and a definitive phase 3 trial to compare margin status and rates of treatment failure after LEEP and CKC is warranted. PMID: 33032824 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 5, 2020 Category: Cancer & Oncology Authors: Cohen PA, Leung Y, Anderson L, van der Griend R, Chivers P, Bilic S, Bittinger S, Brand A, Bulsara MK, Codde J, Eva L, Farrell L, Harker D, Herbst U, Jeffares S, Loh D, McNally O, Mohan GR, Nicholson T, Powell A, Salfinger SG, Simcock B, Stewart C, Silver Tags: Gynecol Oncol Source Type: research

Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy.
CONCLUSIONS: Although second-line therapy for resistant or relapsed low risk GTN is able to achieve complete remission in most cases, time to complete remission for relapsed disease was shorter than for resistant disease. Further studies on the biologic differences between resistant and relapsed disease may clarify the optimal treatment for these clinical situations. PMID: 33023756 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 3, 2020 Category: Cancer & Oncology Authors: Jareemit N, Horowitz NS, Goldstein DP, Berkowitz RS, Elias KM Tags: Gynecol Oncol Source Type: research

No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
CONCLUSION: Decreased SMI during neoadjuvant chemotherapy was not associated with worse outcome in patients with stage III ovarian cancer included in the OVHIPEC-trial. However, a strong association between decreasing SMI and adverse events was found. PMID: 33019981 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 1, 2020 Category: Cancer & Oncology Authors: Ubachs J, Koole SN, Lahaye M, Fabris C, Bruijs L, Schagen van Leeuwen J, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham M, van Dam P, Vuylsteke P, Bastings J, Kruitwagen RFPM, Lambrechts S, Olde Damink SWM, Rensen SS, Van Gorp Tags: Gynecol Oncol Source Type: research

Using machine learning to create prognostic systems for endometrial cancer.
CONCLUSION: This novel machine learning algorithm demonstrates improved prognostic prediction for patients with endometrial cancer. Using machine learning for endometrial cancer allows for the integration of multiple factors to develop a precision prognostication system. PMID: 33019982 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 1, 2020 Category: Cancer & Oncology Authors: Praiss AM, Huang Y, St Clair CM, Tergas AI, Melamed A, Khoury-Collado F, Hou JY, Hu J, Hur C, Hershman DL, Wright JD Tags: Gynecol Oncol Source Type: research

Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors.
PMID: 33019983 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 1, 2020 Category: Cancer & Oncology Authors: Gershenson DM, Cobb LP, Sun CC Tags: Gynecol Oncol Source Type: research

Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
CONCLUSION: A newly developed two-marker ROCA administered every 4 months had lower call-back rates than SOC surveillance. Having established high specificity, the two-marker ROCA score deserves further evaluation for sensitivity in a larger trial. PMID: 33012551 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 30, 2020 Category: Cancer & Oncology Authors: Lentz SE, Powell CB, Haque R, Armstrong MA, Anderson M, Liu Y, Jiang W, Chillemi G, Shaw S, Alvarado MM, Kushi LH, Skates SJ Tags: Gynecol Oncol Source Type: research

Clinical assays for assessment of homologous recombination DNA repair deficiency.
Abstract Homologous recombination DNA repair deficiency (HRD) is a functional defect in homologous recombination DNA repair, arising from germline or somatic mutations in BRCA1/2 or other mechanisms. Cells with HRD are more sensitive to platinum and poly(ADP-ribose) polymerase inhibitors (PARPi). HRD generates permanent changes in the genome with specific, quantifiable patterns ("genomic scars"). Clinical tests for HRD, such as the Myriad genomic instability score and Foundation Medicine loss of heterozygosity test, aim to predict the presence of HRD based on genomic features. Clinical trials of PARPi in...
Source: Gynecologic Oncology - September 30, 2020 Category: Cancer & Oncology Authors: Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF Tags: Gynecol Oncol Source Type: research

Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma.
PMID: 33008583 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 30, 2020 Category: Cancer & Oncology Authors: Rossi EC Tags: Gynecol Oncol Source Type: research

Toxicity after adjuvant therapy for stage III uterine cancer.
CONCLUSION: Chemoradiotherapy is associated with lower mortality compared to single modality therapy and has a similar risk of early and late term toxicities compared to CT, though higher risk of early toxicities compared to RT. PMID: 33008633 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 28, 2020 Category: Cancer & Oncology Authors: Chen LC, Huang Y, Hou JY, Khoury-Collado F, Melamed A, St Clair CM, Tergas AI, Hur C, Hillyer GC, Hershman DL, Wright JD Tags: Gynecol Oncol Source Type: research

Clinical needs for transgender men in the gynecologic oncology setting.
Abstract Transgender men remain at risk for gynecologic malignancies, but are an underserved population. Members of the transgender community experience discrimination and have experiences that contribute to health disparities, including in gynecology and oncology. While efforts have been made within the United States to reduce inequalities experienced by members of this community, many needs in the clinical setting remain. Increased education and training among providers and healthcare professionals, and general improvements towards understanding barriers to health screening and health resource uptake may reduce ...
Source: Gynecologic Oncology - September 28, 2020 Category: Cancer & Oncology Authors: Stenzel AE, Moysich KB, Ferrando CA, Starbuck KD Tags: Gynecol Oncol Source Type: research

Patterns of use and outcomes of sentinel lymph node mapping for patients with high-grade endometrial cancer.
PMID: 33004215 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 27, 2020 Category: Cancer & Oncology Authors: Nasioudis D, Albright BB, Roy A, Ko EM, Giuntoli RL, Haggerty AF, Cory L, Kim SH, Morgan MA, Latif NA Tags: Gynecol Oncol Source Type: research

Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
CONCLUSIONS: The results confirm the dominant role of CA125 for identifying malignancy, and suggest that other markers (HE4, CA72.4, CA15.3 and LAP) may help to distinguish between stage I and stage II-IV malignancies. However, further research is needed, also to investigate the added value over clinical and ultrasound predictors of malignancy, focusing on the differentiation between subtypes of malignancy. PMID: 32994054 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 25, 2020 Category: Cancer & Oncology Authors: Landolfo C, Achten ETL, Ceusters J, Baert T, Froyman W, Heremans R, Vanderstichele A, Thirion G, Van Hoylandt A, Claes S, Oosterlynck J, Van Rompuy AS, Schols D, Billen J, Van Calster B, Bourne T, Van Gorp T, Vergote I, Timmerman D, Coosemans A Tags: Gynecol Oncol Source Type: research

Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
PMID: 32994055 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 25, 2020 Category: Cancer & Oncology Authors: Chan JK, Liang SY, Kapp DS, Chan JE, Herzog TJ, Coleman RL, Monk BJ, Richardson MT Tags: Gynecol Oncol Source Type: research

Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG study.
lhede P, Åvall-Lundqvist E Abstract OBJECTIVE: Vulvar cancer affects mainly elderly women and with an ageing population the incidence has increased. We explored the primary treatment patterns and relative survival of patients with vulvar squamous cell carcinoma (VSCC) by stage and age-group. METHODS: A population-based nationwide study on women diagnosed with VSCC between 2012 and 2016 and registered in the Swedish Quality Registry for Gynecologic Cancer (SQRGC). Main outcome was 5-year relative survival (RS) estimated by the Pohar Perme method. The relative risk of excess mortality (EMRR) between diffe...
Source: Gynecologic Oncology - September 24, 2020 Category: Cancer & Oncology Authors: Hellman K, Holmberg E, Bjurberg M, Borgfeldt C, Dahm-Kähler P, Flöter Rådestad A, Hjerpe E, Högberg T, Marcickiewicz J, Rosenberg P, Stålberg K, Tholander B, Kjølhede P, Åvall-Lundqvist E Tags: Gynecol Oncol Source Type: research

An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
A, Poveda A Abstract OBJECTIVE: Olaparib is a potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1, 2, and 3 with potential activity in endometrial cancer (EC). METHODS: In this window-of-opportunity trial, women with operable type 1 EC received olaparib oral tablets (300mg) twice daily for 28days before surgery. The primary objective was to evaluate the effects of olaparib on EC in tissue samples taken at baseline and at treatment completion. Signal of activity was defined as significant changes in the expression of the cell cycle-related proteins cyclin D1, Ki67, and cleaved caspase-3. RESULTS: A t...
Source: Gynecologic Oncology - September 24, 2020 Category: Cancer & Oncology Authors: Romero I, Rubio MJ, Medina M, Matias-Guiu X, Santacana M, Schoenenberger JA, Guerra EM, Cortés A, Minig L, Coronado P, Cueva JF, Gómez L, Malfettone A, Sampayo M, Llombart-Cussac A, Poveda A Tags: Gynecol Oncol Source Type: research

LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
CONCLUSION: Together, these data demonstrate that WNT7B/FZD5-LGR4/ELF3 axis maintains HGSOC cell epithelial phenotype and stem-like traits; targeting this axis may prevent HGSOC metastasis. PMID: 32980127 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 23, 2020 Category: Cancer & Oncology Authors: Wang Z, Yin P, Sun Y, Na L, Gao J, Wang W, Zhao C Tags: Gynecol Oncol Source Type: research

Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals.
CONCLUSIONS: More than one third of patients with gynecologic cancer at three affiliated New York City hospitals experienced a treatment delay, change or cancellation during the first two months of the COVID-19 pandemic. Among the three New York City boroughs represented in this study, likelihood of gynecologic oncology treatment modifications correlated with the case burden of COVID-19. PMID: 32981694 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 23, 2020 Category: Cancer & Oncology Authors: Frey MK, Fowlkes RK, Badiner NM, Fishman D, Kanis M, Thomas C, Christos PJ, Martin P, Gamble C, Balogun OD, Cardenes H, Gorelick C, Pua T, Nguyen L, Holcomb K, Chapman-Davis E Tags: Gynecol Oncol Source Type: research

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
We present long-term safety data for niraparib from the ENGOT-OV16/NOVA trial. METHODS: This multicenter, double-blind, randomized, controlled phase III trial evaluated the efficacy and safety of niraparib for the treatment of recurrent ovarian cancer. Patients were randomly assigned 2:1 to receive either once-daily niraparib 300 mg or placebo. Two independent cohorts were enrolled based on germline BRCA mutation status. The primary endpoint was progression-free survival, reported previously. Long-term safety data were from the most recent data cutoff (September 2017). RESULTS: Overall, 367 patients received...
Source: Gynecologic Oncology - September 23, 2020 Category: Cancer & Oncology Authors: Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Herráez AC, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA Tags: Gynecol Oncol Source Type: research

Dose-escalated intensity modulated radiation therapy in patients with locally-advanced vulvar cancer - does it increase response rate?
CONCLUSION: Dose-escalated IMRT for locally-advanced vulvar cancer is well tolerated, with rates of cCR and pCR that compare favorably with published data. PMID: 32981696 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 23, 2020 Category: Cancer & Oncology Authors: Richman AH, Vargo JA, Ling DC, Sukumvanich P, Berger JL, Boisen MM, Edwards R, Taylor SE, Courtney-Brooks MB, Olawaiye A, Orr BC, Beriwal S Tags: Gynecol Oncol Source Type: research

Perioperative outcomes and disparities in utilization of sentinel lymph node biopsy in minimally invasive staging of endometrial cancer.
CONCLUSION: We identified significant disparities in the utilization of SLNB, as well as evidence that this less-invasive technique is associated with lower rates of certain perioperative complications. Equitable access to this emerging technique could lessen disparate outcomes. PMID: 32981697 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 23, 2020 Category: Cancer & Oncology Authors: Albright BB, Nasioudis D, Byrne ME, Latif NA, Ko EM, Haggerty AF Tags: Gynecol Oncol Source Type: research

Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
Abstract OBJECTIVE: To characterize factors associated with high-cost inpatient admissions for ovarian cancer. METHODS: Operative hospitalizations for ovarian cancer patients ≥65 years of age were identified using the 2010-2017 National Inpatient Sample. Admissions with high-cost were defined as those incurring ≥90th percentile of hospitalization costs each year, while the remainder were considered low-cost. Multivariable logistic regression models were developed to assess independent predictors of being in the high-cost cohort. RESULTS: During the study period, an estimated 58,454 patients me...
Source: Gynecologic Oncology - September 22, 2020 Category: Cancer & Oncology Authors: Manrriquez E, Mandelbaum A, Aguayo E, Zakhour M, Karlan B, Benharash P, Cohen JG Tags: Gynecol Oncol Source Type: research

The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
CONCLUSIONS: This is the first study, suggesting the novel triazene drug CT913 as enhancer drug for extending the therapeutic spectrum of PARPi. PMID: 32980128 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 22, 2020 Category: Cancer & Oncology Authors: Wichmann C, Klotz DM, Zeiler HJ, Hilger RA, Grützmann K, Krüger A, Aust D, Wimberger P, Kuhlmann JD Tags: Gynecol Oncol Source Type: research

A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States.
CONCLUSION: Improved screening coverage has the largest potential for reducing cervical cancer incidence, though there is also a role for improved recall procedures and screening sensitivity. PMID: 32977987 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 21, 2020 Category: Cancer & Oncology Authors: Landy R, Mathews C, Robertson M, Wiggins CL, McDonald YJ, Goldberg DW, Scarinci IC, Cuzick J, Sasieni PD, Wheeler CM Tags: Gynecol Oncol Source Type: research

Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients.
CONCLUSIONS: This finding, combined with previous epidemiological literature and tissue-based analytical studies, provides further evidence that the small, isodiametric particles that dominate TCBP can migrate from the perineum and become lodged in distal structures in the female reproductive tract, where they may lead to an increased risk of developing ovarian carcinoma. PMID: 32977988 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 21, 2020 Category: Cancer & Oncology Authors: Johnson KE, Popratiloff A, Fan Y, McDonald S, Godleski JJ Tags: Gynecol Oncol Source Type: research

Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
Abstract OBJECTIVES: 1.) To compare frequency of HIPEC use in ovarian cancer treatment before and after publication of the phase III study by van Driel et al. in January 2018. 2.) To compare associated rates of hospital-based outcomes, including length of stay, intensive care unit (ICU) admission, complications, and costs in ovarian cancer surgery with or without HIPEC. METHODS: We queried Vizient's administrative claims database of 550 US hospitals for ovarian cancer surgeries from January 2016-January 2020 using ICD-10 diagnosis and procedure codes. Sodium thiosulfate administration was used to identify HIP...
Source: Gynecologic Oncology - September 21, 2020 Category: Cancer & Oncology Authors: Charo LM, Jou J, Binder P, Hohmann SF, Saenz C, McHale M, Eskander RN, Plaxe S Tags: Gynecol Oncol Source Type: research

The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes.
PMID: 32972783 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 21, 2020 Category: Cancer & Oncology Authors: Chino J, Annunziata CM, Beriwal S, Bradfield L, Erickson BA, Fields EC, Fitch J, Harkenrider MM, Holschneider CH, Kamrava M, Leung E, Lin LL, Mayadev JS, Morcos M, Nwachukwu C, Petereit D, Viswanathan AN Tags: Gynecol Oncol Source Type: research

Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
CONCLUSIONS: Our findings will aid interpretation of EORTC QLQ-C30 scores in ovarian cancer and inform sample size calculations in future ovarian cancer trials with endpoints that are based on EORTC QLQ-C30 scales. PMID: 32972782 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 20, 2020 Category: Cancer & Oncology Authors: Musoro JZ, Coens C, Greimel E, King MT, Sprangers MAG, Nordin A, van Dorst EBL, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A, EORTC Gynecological and Quality of Life Groups Tags: Gynecol Oncol Source Type: research

Management and outcomes of primary vaginal Cancer.
Abstract OBJECTIVE: To analyze clinical characteristics and survival of patients with primary vaginal cancer. METHODS: Retrospective analysis of patients with primary squamous, adenocarcinoma and adenosquamous cell carcinoma of the vagina identified from the Mayo Clinic Cancer Registry between 1998 and 2018. RESULTS: A total of 124 patients were identified: stage I, 39 patients; stage II, 44, stage III, 20 and stage IV, 21. Patients with stage III and IV were older as compared to stage I and II. (mean ages 61 vs 67) (p = 0.024). Squamous cell carcinoma made up 71% of tumors. History of other ma...
Source: Gynecologic Oncology - September 20, 2020 Category: Cancer & Oncology Authors: Yang J, Delara R, Magrina J, Magtibay P, Langstraat C, Dinh T, Karlin N, Vora SA, Butler K Tags: Gynecol Oncol Source Type: research

Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.
Abstract OBJECTIVE: There is great need for better risk stratification in vulvar squamous cell carcinoma (VSCC). Our aim was to define the prognostic significance of stratifying VSCC based on p16 and p53 immunohistochemistry (IHC) as surrogate markers for HPV and TP53 mutations. METHODS: A large retrospective cohort of surgically treated women with primary VSCC was used. VSCC were classified into three subtypes: HPV-positive (HPVpos), HPV-negative/p53 mutant (HPVneg/p53mut), and HPV-negative/p53 wildtype (HPVneg/p53wt). Overall survival (OS), relative survival (RS), and recurrence-free period (RFP) were depic...
Source: Gynecologic Oncology - September 20, 2020 Category: Cancer & Oncology Authors: Kortekaas KE, Bastiaannet E, van Doorn HC, de Vos van Steenwijk PJ, Ewing-Graham PC, Creutzberg CL, Akdeniz K, Nooij LS, van der Burg SH, Bosse T, van Poelgeest MIE Tags: Gynecol Oncol Source Type: research